Homeward Selected to Receive Award for up to $12 Million from ARPA-H's PARADIGM Program
Homeward ®, a company committed to rearchitecting the delivery of health and care in partnership with communities everywhere, starting in rural America, today announced it has been awarded up to $12 million in research funding to serve as a lead performer for The Advanced Research Projects Agency for Health ( ARPA-H) Platform Accelerating Rural Access to Distributed and InteGrated Medical Care (PARADIGM) program. The program is a 5-year project to develop a scalable mobile platform that can bring sophisticated medical services – including perinatal care, advanced wound care, and more – outside of a hospital setting to the doorstep of even the most remote, rural populations.
'Rural America faces some of the greatest healthcare challenges in our country, with higher mortality rates and limited access to essential care due to a shortage of hospitals, specialty clinics, and healthcare workers,' said Homeward Co-Founder and President Amar Kendale. 'At Homeward, our mission is to rearchitect the delivery of health and care in partnership with communities in rural America, and the PARADIGM program is a critical step in advancing this mission. With the rapid rise of artificial intelligence and other health technologies, we have an opportunity to bring advanced medical services and specialty care directly to those who need it most – with the potential to leapfrog other markets – ensuring no community is left behind.'
PARADIGM is funding part of Homeward's Advanced Research Program, a cornerstone effort to advance healthcare solutions for rural communities where access is limited. As AI and health technology continue to evolve, rural healthcare providers often face significant barriers to adoption due to lack of solutions designed for their unique needs. Homeward's new research and development initiative will bring technology that is specifically adapted to the needs of rural communities so that it will make a real difference in peoples' lives, in partnership with rural providers, academic centers and other community stakeholders. Research and development projects led through Homeward's Advanced Research Program are designed to make health technology more accessible, equitable and impactful for the millions of Americans living in rural areas.
'Solving the rural healthcare crisis requires new approaches and ideas designed with rural communities in mind, which is the driving force behind Homeward's Advanced Research Program,' said Vice President of Advanced Research Programs at Homeward Fred Barrigar. 'Through initiatives like PARADIGM, we're developing and testing solutions with partners in rural communities where traditional healthcare models fall short. From improving how treatments are delivered to advancing diagnostic tools, our goal is to create scalable innovations that improve care delivery and accessibility in rural communities.'
The PARADIGM program anchors this initiative by addressing all three of the Advanced Research Program's focus areas: workforce transformation, advanced therapeutic delivery, and distributed diagnostics. The project will focus on defining clinical services, collaborating with technology partners to develop and implement solutions, and conducting clinical research studies with subcontractor grant organizations, including the University of Minnesota and Mobile Health Map (MHM) at Harvard Medical School.
MHM is a national collaborative that helps mobile clinics measure, improve, and communicate their impact. MHM will focus on ensuring the PARADIGM care delivery model reflects the real-world needs of rural communities. The University of Minnesota will serve as a co-principal investigator, leading efforts to evaluate the PARADIGM program's clinical effectiveness and effect on reducing healthcare disparities.
'The University of Minnesota is proud to partner with Homeward and advance the PARADIGM program to understand how we might best deliver care to rural communities in Minnesota,' said Associate Professor of Medicine at the University of Minnesota and faculty in the Program for Health Disparities Research Dr. Elizabeth Rogers, who is leading the evaluation of this project. 'Research is critical to understanding what works and its impact so we can improve care delivery in meaningful ways. By turning insights into thoughtful programs, we aim to eliminate the healthcare disparities that rural communities have faced for far too long.'
About Homeward
Homeward is rearchitecting the delivery of health and care for rural Americans by partnering with payers, providers, and community organizations. By taking full financial accountability for clinical outcomes and the total cost of care across rural counties, Homeward aligns incentives and strengthens local healthcare ecosystems. The Homeward Navigation™ platform uses advanced analytics to connect members to the right care and local resources that address social determinants of health and improve holistic health outcomes. Since many rural communities lack adequate clinical capacity, Homeward employs care teams that supplement local practices and reach people who cannot access care otherwise. As a public benefit corporation and B Corp™ certified company, Homeward's mission and business model are aligned to address the healthcare, economic, and demographic challenges that make it harder for rural Americans to stay healthy. For more information, please visit www.homewardhealth.com.
SOURCE: Homeward
Copyright Business Wire 2025.
PUB: 02/12/2025 10:15 AM/DISC: 02/12/2025 10:15 AM
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
32 minutes ago
- Yahoo
BioInvent Announces Promising Phase 1 Data of BI-1206 in Combination with KEYTRUDA(R) (pembrolizumab) in Solid Tumors
The Phase 1 dose escalation has been completed, and results show encouraging early signs of clinical activity in solid tumors with one complete response, one long-lasting partial response, and 11 patients with stable disease. Based on this promising data, BioInvent plans to initiate Phase 2a expansion cohorts to treat patients with advanced or metastatic non-small cell lung cancer (NSCLC) or uveal melanoma, in the front line in combination with KEYTRUDA® (pembrolizumab). Patient enrollment is expected to begin H2 2025. LUND, SE / / June 11, 2025 / BioInvent International AB ("BioInvent") (Nasdaq Stockholm: BINV), a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, today announced updated, positive Phase 1 data of intravenous (IV) and subcutaneous (SC) BI-1206 in combination with MSD's (Merck & Co., Inc., Rahway, NJ, USA) anti-PD-1 therapy KEYTRUDA® (pembrolizumab) in heavily pre-treated patients with solid tumors. Based on the encouraging data, the company intends to expand its investigation of BI-1206 SC in combination with pembrolizumab in earlier lines of treatment, by initiating a Phase 2a study arm with focus on first-line patients with advanced or metastatic NSCLC and uveal melanoma. The Phase 2a study is planned to be initiated during H2 2025. The updated Phase 1 data in heavily pre-treated patients - including several lines of IO agents - show encouraging clinical activity of the combination, with one patient with metastatic cutaneous melanoma experiencing a complete response (CR), one patient with metastatic uveal melanoma achieving a long-lasting partial response (PR) and 11 patients experiencing stable disease (SD) out of a total of 36 evaluable patients. The product was well-tolerated, enabling continued dose expansion exploring the use of higher dose levels. The trial is part of BioInvent's strategy to transition from IV dosing to SC formulation for BI-1206 allowing slower systemic entry and prolonged time on target to enhance the products therapeutic impact and improve safety and tolerability of the combination. The Phase 1 data in solid tumors corroborate preclinical findings that BI-1206 significantly enhances the effect of anti-PD-1. Based on this evidence, MSD and BioInvent have agreed to further investigate the synergies between BI-1206 and pembrolizumab in earlier lines of treatment. The upcoming Phase 2a study of BI-1206 in combination with pembrolizumab is planned to be performed in treatment-naïve patients with NSCLC and uveal melanoma. "We are highly encouraged by the clinical responses emerging from our solid tumor program which support the broad utility of combining subcutaneous BI-1206 with pembrolizumab in a range of solid tumors," said Martin Welschof, Chief Executive Officer of BioInvent. "The strong signals we have observed in heavily pre-treated patients support the idea that BI-1206 could be used to improve the activity of pembrolizumab across different tumor types, and we therefore look forward to initiating our Phase 2a study in the high unmet medical need of non-small cell lung cancer." KEYTRUDA® is a registered trademark of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA. ###About NSCLC and combination treatment with targeting FcyRIIBNSCLC is the most common type of lung cancer, accounting for about 85% of all lung cancer cases. While checkpoint inhibitors are widely accepted and can produce durable responses in NSCLC, the overall response rate remains low, rarely exceeding 25%. A common resistance mechanism in cancer is the binding and degradation of therapeutic antibodies against PD-1 such as pembrolizumab by FcγRIIB expressing immune cells. Therefore, based on preclinical and early clinical data, the company believes that resistance or lack of response to anti-PD-1 treatment may be overcome by FcγRIIB blockade in particular in subjects who have never been exposed to anti PD-1 agents. About BI-1206BI-1206 is one of BioInvent's lead drug candidates and is developed to re-establish the clinical effect of existing cancer treatments such as pembrolizumab and rituximab. The drug candidate is evaluated in two separate clinical programs, one for the treatment of solid tumors and one for the treatment of non-Hodgkin's lymphoma (NHL, a type of blood cancer). BI-1206 in solid tumorsClinical Phase 1/2a study with BI-1206 in combination with MSD's (Merck & Co., Inc., Rahway, NJ, USA) anti-PD-1 therapy KEYTRUDA® (pembrolizumab) in heavily pre-treated patients with solid tumors (NCT04219254) is ongoing. The concluded Phase 1 dose escalation study in heavily pre-treated patients shows encouraging clinical activity of the combination, including one CR in metastatic melanoma, one PR in uveal melanoma and 11 patients experiencing SD out of a total of 36 evaluable patients. The product was well-tolerated, enabling continued dose expansion exploring the use of higher dose levels. For further details, please refer to the ASCO 2024 poster on the company web site: Out of the patients with stable disease as best response, one patient with long-lasting metastatic melanoma, who had previously progressed on nivolumab treatment, remained a stable disease throughout the two-year study duration with BI-1206 and pembrolizumab. The planned Phase 2a study of BI-1206 in combination with pembrolizumab for treatment-naïve patients with NSCLC and uveal melanoma consists of two parts: a signal seeking phase and a dose optimization phase. In the first signal seeking phase, up to 30 NSCLC and 12 uveal melanoma patients will receive fixed doses of BI-1206 and pembrolizumab every 21 days for three treatment cycles. Patients showing clinical benefit by Week 9 can continue therapy for up to 32 additional cycles, while those with disease progression will not proceed further. About BioInventBioInvent International AB (Nasdaq Stockholm: BINV) is a clinical-stage biotech company that discovers and develops novel and first-in-class immuno-modulatory antibodies for cancer therapy, with currently five drug candidates in six ongoing clinical programs in Phase 1/2 trials for the treatment of hematological cancer and solid tumors. The Company's validated, proprietary F.I.R.S.T™ technology platform identifies both targets and the antibodies that bind to them, generating many promising new immune-modulatory candidates to fuel the Company's own clinical development pipeline and providing licensing and partnering opportunities. The Company generates revenues from research collaborations and license agreements with multiple top-tier pharmaceutical companies, as well as from producing antibodies for third parties in the Company's fully integrated manufacturing unit. More information is available at For further information, please contact:Cecilia Hofvander, VP Investor RelationsPhone: +46 (0)46 286 85 50Email: International AB (publ)Co. Reg. No.: 556537-7263Visiting address: Ideongatan 1Mailing address: 223 70 LUNDPhone: +46 (0)46 286 85 The press release contains statements about the future, consisting of subjective assumptions and forecasts for future scenarios. Predictions for the future only apply as the date they are made and are, by their very nature, in the same way as research and development work in the biotech segment, associated with risk and uncertainty. With this in mind, the actual outcome may deviate significantly from the scenarios described in this press release. Attachments BioInvent Announces Promising Phase 1 Data of BI-1206 in Combination with KEYTRUDA® (pembrolizumab) in Solid Tumors SOURCE: BioInvent International View the original press release on ACCESS Newswire Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Yahoo
an hour ago
- Yahoo
MaxCyte and Ori Biotech Collaborate to Improve Manufacturing Efficiencies and Broaden Adoption of Autologous Cellular Therapies
MaxCyte and Ori Biotech successfully integrate their ExPERT™ and IRO® platforms to improve the yield of gene-edited T cells and shorten manufacturing timelines ROCKVILLE, Md. and LONDON, June 11, 2025 (GLOBE NEWSWIRE) -- MaxCyte, Inc. (Nasdaq: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, and Oribiotech Ltd. (Ori), a leader in advanced cell and gene therapy (CGT) manufacturing technology, today announced a strategic collaboration aimed at enhancing efficiency, scalability, and productivity in cell therapy manufacturing. This collaboration combines the MaxCyte ExPERT™ platform and proven Flow Electroporation® technology, widely recognized for its efficient and scalable transfection capabilities, utilized in over 19 active clinical and commercial programs, with Ori's innovative next-generation cell therapy manufacturing platform, IRO® (ee-RO). The collaboration will specifically evaluate how the IRO platform can optimize the yield and streamline the manufacturing timelines of MaxCyte-engineered primary T cells compared to traditional post-electroporation cell expansion processes. As a key component of this joint effort, Ori and MaxCyte have selected CD19 CAR expression via CRISPR knock-in in activated T cells as the test system for initial evaluation. MaxCyte's technology offers unparalleled flexibility and efficiency in transfecting cells at clinical scale, seamlessly integrating with diverse upstream and downstream processes within cell therapy workflows. The IRO platform complements this by introducing automated fluid handling, customizable mixing, and the OriConnect® tubeless sterile connection system, enhancing cell culture efficiency and scalability. Together, these complementary technologies provide therapy developers with a powerful toolkit to achieve clinically relevant quantities of gene-edited T cells more rapidly and efficiently. Maher Masoud, President and CEO of MaxCyte, commented, 'We are excited to collaborate with the team at Ori Biotech, combining our respective strengths and innovative technologies to significantly enhance manufacturing processes. This partnership underscores our commitment to enabling therapy developers to more effectively address the evolving demands of cell therapy manufacturing, ultimately accelerating the availability of transformative treatments for patients.''Our partnership with MaxCyte is another example of Ori's dedication to providing flexible and scalable solutions that address critical challenges in cell and gene therapy manufacturing,' said Jason C. Foster, CEO of Ori Biotech. 'By integrating modular, best-of-breed technologies, we're raising the standard of manufacturing by enhancing commercial viability. Ultimately, this collaboration helps bring cell therapies to patients faster, more reliably, and at greater scale.' Through their shared commitment to innovation and industry collaboration, MaxCyte and Ori Biotech are enabling developers of advanced therapies to adopt integrated, best-of-breed solutions, accelerating the path from research to commercialization and making next-generation treatments more accessible to patients globally. About MaxCyte At MaxCyte®, we are committed to building better cells together. As a leading cell-engineering company, we are driving the discovery, development and commercialization of next-generation cell therapies. Our best-in-class Flow Electroporation® technology and SeQure DX™ gene editing risk assessment services enable precise, efficient and scalable cell engineering. Supported by expert scientific, technical and regulatory guidance, our platform empowers researchers from around the world to engineer diverse cell types and payloads, accelerating the development of safe and effective treatments for human health. For more than 25 years, we've been advancing cell engineering, shaping the future of medicine. Learn more at and follow us on X and LinkedIn. About Ori Biotech Ori Biotech is a London and Philadelphia-based manufacturing technology company on a mission to enable widespread patient access to life-saving cell and gene therapies. IRO®, Ori's next-generation manufacturing platform automates better biology, accelerates product development and enables therapy developers to scale their products' clinical and commercial impact by seamlessly transitioning from R&D to GMP on one platform. The promise of the innovative Ori platform is to automate cell therapy manufacturing, increasing throughput, improving quality and decreasing costs by combining proprietary hardware, consumables, software, data and analytics. For news and updates, visit Forward Looking Statements This press release contains forward-looking statements within the meaning of the 'safe harbor' provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding the anticipated benefits, outcomes, and impact of the collaboration between MaxCyte and Ori Biotech; the potential for improving clinical success and commercial viability through new manufacturing standards; and the intention to accelerate development timelines, increase access to next-generation cell therapies, and deliver transformative treatments to patients globally. These statements are based on current expectations, estimates, forecasts, and projections about the industry and markets in which MaxCyte operates, as well as management's current beliefs and assumptions. Words such as 'aims,' 'expects,' 'anticipates,' 'intends,' 'plans,' 'believes,' 'seeks,' 'estimates,' 'may,' 'will,' 'should,' 'continue,' and variations of such words and similar expressions are intended to identify forward-looking statements. These statements are not guarantees of future performance and involve certain risks, uncertainties, and assumptions that are difficult to predict and are often beyond the control of the companies involved. Actual outcomes and results may differ materially from those expressed or implied in these forward-looking statements due to various factors, including changes in market conditions, technological advancements, regulatory developments, and the success of ongoing research and evaluation efforts. Risks and uncertainties related to our business are described in greater detail in Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2024, filed with the Securities and Exchange Commission ('SEC') on March 11, 2025, as well as in discussions of potential risks, uncertainties, and other important factors in the other filings that we make with the Securities and Exchange Commission from time to time, including in our Form 10-Q for the quarter ended May 8, 2025. These documents are available through the Investor Menu, Financials section, under 'SEC Filings' on the Investors page of our website at Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Except as required by law, MaxCyte does not undertake any obligation to update or revise any forward-looking statements to reflect new information, events, or circumstances after the date of this release. MaxCyte Contacts: US IR AdviserGilmartin GroupDavid Deuchler, CFA+1 415-937-5400ir@ Oak Street CommunicationsKristen Whitekristen@ Nominated Adviser and Joint Corporate BrokerPanmure LiberumEmma Earl / Freddy CrossleyCorporate BrokingRupert Dearden+44 (0)20 7886 2500 UK IR AdviserICR HealthcareMary-Jane ElliottChris Welsh+44 (0)203 709 5700maxcyte@ Ori Biotech Contact: Debby Betzmedia@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Upturn
an hour ago
- Business Upturn
New Study Finds Masimo SedLine® Brain Function Monitoring Offers Significant Advantages During Pediatric Anesthesia
Neuchatel, Switzerland: Masimo (NASDAQ: MASI) today announced the findings of a randomized clinical trial published in JAMA Pediatrics in which Dr. Yasuko Nagasaka and colleagues at Tokyo Women's Medical University demonstrated the ability of electroencephalogram (EEG)-guided anesthesia, using Masimo SedLine® Brain Function Monitoring, to improve anesthesia administration in children undergoing surgery.1 The researchers found that the use of SedLine led to a significant reduction in the amount of a commonly used inhalation anesthetic (sevoflurane) needed to maintain anesthesia in pediatric patients, reducing their exposure to the drug. In turn, the patients experienced a significantly lower rate of pediatric anesthesia emergence delirium, or PAED, which commonly manifests in confusion, agitation, or hallucinations experienced during recovery. When compared with standard practice, children monitored with SedLine also regained consciousness faster and could be safely discharged to the post-anesthesia care unit, or PACU, sooner – time savings that, the researchers noted, may represent additional cost savings. In sum, the researchers found that Masimo SedLine helped to make pediatric anesthesia safer, more efficient, and more cost effective. This press release features multimedia. View the full release here: Masimo SedLine® Brain Function Monitoring Children monitored with SedLine were exposed to an average of 1.4 MAC hours less sevoflurane and had a 14% lower incidence rate of PAED. On average, they regained consciousness 53% sooner and were discharged from the PACU 48% sooner. The time saved led to an estimated cost savings of $240 to $920 per patient. PAED is a frequent and clinically significant complication in pediatric anesthesia,2 often leading to short-term distress among pediatric patients, parents, and staff. Some of the negative postoperative behaviors can persist for weeks or months.3 Exposure to commonly used volatile anesthetics like sevoflurane gas has been shown to contribute to PAED.4 In current standard practice, a fixed amount of sevoflurane, 1.0 minimum alveolar concentration (MAC), is used to maintain pediatric anesthesia, but as the authors note, that may be excessive.5 Dr. Nagasaka and her team hypothesized that by using bilateral EEG – in particular, the waveforms and multitaper density spectral array (DSA) spectrograms displayed by Masimo SedLine – to guide sevoflurane titration, the amount needed to induce and maintain appropriate sedation could be reduced, thereby reducing the incidence of PAED. In the study, children aged 1 to 6 years scheduled for elective surgery involving at least 30 minutes of general anesthesia at the largest children's hospital in Japan were randomly assigned to an experimental group (n=91), whose anesthesia was guided by Masimo SedLine, or a control group (n=86), whose anesthesia was guided using standard practice, i.e. a fixed sevoflurane dosage of 1.0 MAC. The researchers recorded the amount of sevoflurane exposure for each patient and the time elapsed between important events including intubation, extubation, arrival and discharge from the PACU, and emergence from anesthesia. All patients were assessed for PAED by clinicians blinded to the treatment assignment, using a standard scale. The researchers found that the incidence of PAED was significantly lower among patients in the SedLine group, affecting 21% of patients vs. 35% of patients in the control group (p=0.04). SedLine group patients were exposed to significantly less sevoflurane, by an average 1.4 MAC hours. They were extubated sooner, by an average of 3.3 minutes, regained consciousness sooner, by an average of 21.4 minutes, and were discharged from the PACU sooner, by an average of 16.5 minutes. The researchers estimated that the reduction in time spent in the OR and PACU, of approximately 20 minutes, may represent a cost savings of $240 to $920 (USD) per case. The authors concluded, 'EEG-guided management of general anesthesia reduced sevoflurane exposure and pediatric anesthesia emergence delirium in children, with faster emergence and shorter post-anesthesia care unit stays. The findings suggest that high concentrations of sevoflurane for induction followed by routine use of 1.0-MAC sevoflurane for maintenance may be excessive.' They also noted that 'with EEG monitoring, parents and guardians may be reassured that health care professionals can make an active effort to reduce and minimize a child's exposure to anesthetic drugs.' A similar study in 2022 by Long et al. – one of the first to investigate the impact of EEG-guided anesthesia on children undergoing surgery – found that pediatric patients monitored with SedLine experienced significantly fewer EEG patterns of profound brain inactivity, known as burst suppression. Burst Suppression has also been associated with adverse outcomes, including postoperative delirium.6 Yasuko Nagasaka, Professor of Anesthesia at Tokyo Women's Medical University and the new study's senior author, commented, 'While general anesthesia is necessary for pediatric patients undergoing surgery, parents and guardians may express concerns about their child's exposure to anesthetic drugs. We can now offer reassurance by explaining that modern medical technologies, such as EEG-guided anesthesia care, help minimize anesthetic exposure, potentially reducing the incidence of pediatric emergence delirium (PAED) and supporting earlier awakening and recovery from unconsciousness.' 'It is important to recognize,' continued Dr. Nagasaka, 'that increasing the depth of anesthesia is relatively easy to learn. On the other hand, developing the confidence and skill to safely reduce anesthesia requires deeper understanding. Our results may offer a great step forward towards the improvement of our common practice, which may lead to the development of guidelines for EEG monitoring in pediatric areas to eventually mandate EEG monitoring during general anesthesia in the future. But comprehensive training in EEG-guided anesthesia should be considered a critical next step for the entire anesthesia community.' Dean Kurth, MD, attending anesthesiologist at Children's Hospital of Philadelphia and Professor of Anesthesiology and Critical Care Medicine at the University of Pennsylvania Perelman School of Medicine, added, 'This study by Miyasaka et al. confirms the growing realization by pediatric anesthesiologists worldwide that more anesthesia drug is being administered to children than necessary, which has negative consequences. As the authors have shown, SedLine EEG data can help clinicians provide more precise anesthetic drug dosing for each child and improves outcomes.' @Masimo | #Masimo References Miyasaka K, Suzuki Y, Brown E, Nagasaka Y. EEG-Guided Titration of Sevoflurane and Pediatric Anesthesia Emergence Delirium. JAMA Pediatrics. April 21, 2025. DOI: 10.1001/jamapediatrics.2025.0517. Cole JW, Murray DJ, McAllister JD, Hirshberg GE. Emergence behavior in children: defining the incidence of excitement and agitation following anaesthesia. Paediatr Anaesth. 2002;12(5):442-447. DOI:10.1046/j.1460-9592.2002.00868.x. Davis L, Qi TS, and Ng A. Emergence delirium: an overview with an emphasis on the use of electroencephalography in its management. Anest Pain Med. 2024;19(Suppl 1):S87-95. DOI: 10.17085/apm.24013. Mason KP. Paediatric emergence delirium: a comprehensive review and interpretation of the literature. Br J Anaesth. 2017;118(3):335-343. DOI: 10.1093/bja/aew477. Goddard N, Smith D. Unintended awareness and monitoring of depth of anaesthesia. Contin Educ Anaesth Crit Care Pain. 2013;13(6):213-217. Long MHY, Lim EHL, Balanza GA, Allen JC, Purdon PL, and Bong CL. Sevoflurane requirements during electroencephalogram (EEG)-guided vs. standard anesthesia care in children: A randomized controlled trial. J Clin Anesth. 27 Jun 2022. DOI: About Masimo Masimo (NASDAQ: MASI) is a global medical technology company that develops and produces a wide array of industry-leading monitoring technologies, including innovative measurements, sensors, patient monitors, and automation and connectivity solutions. Our mission is to improve life, improve patient outcomes, reduce the cost of care, and take noninvasive monitoring to new sites and applications. Masimo SET® Measure-through Motion and Low Perfusion™ pulse oximetry, introduced in 1995, has been shown to outperform other pulse oximetry technologies in over 100 independent and objective studies, which can be found at Masimo SET® is estimated to be used on more than 200 million patients around the world each year and is the primary pulse oximetry at all 10 top U.S. hospitals as ranked in the 2025 Newsweek World's Best Hospitals listing. Additional information about Masimo and its products may be found at Forward-Looking Statements This press release includes forward-looking statements as defined in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, in connection with the Private Securities Litigation Reform Act of 1995. Forward-looking statements are statements other than statements of historical facts that address activities, events or developments that we expect, believe or anticipate will or may occur in the future. These forward-looking statements include, among others, statements regarding the performance of SedLine to achieve certain results including the incidence of pediatric emergence delirium, earlier awakening, recovery from unconsciousness, or cost savings; the rate of adoption of SedLine technology by pediatric anesthesiologists for use during anesthesia administration in children undergoing surgery; and other matters that do not relate strictly to historical facts or statements of assumptions underlying any of the foregoing. These statements are often identified by the use of words such as 'anticipate,' 'believe,' 'continue,' 'could,' 'estimate,' 'expect,' 'intend,' 'may,' 'on-going,' 'opportunity,' 'plan,' 'potential,' 'predicts,' 'forecast,' 'project,' 'seek,' 'should,' 'will,' or 'would,' the negative versions of these terms and similar expressions or variations, but the absence of such words does not mean that a statement is not forward-looking. These forward-looking statements are based on current expectations about future events affecting us and are subject to risks and uncertainties, all of which are difficult to predict and many of which are beyond our control and could cause our actual results to differ materially and adversely from those expressed in our forward-looking statements as a result of various risk factors, including, but not limited to: the highly competitive nature of the markets in which we sell our products and technologies; the ability to obtain regulatory approvals; the lack of acceptance of any of our current or future products and technologies; and other factors discussed in the 'Risk Factors' section of our most recent periodic reports filed with the Securities and Exchange Commission ('SEC'), including our most recent Form 10-K and Form 10-Q, all of which you may obtain for free on the SEC's website at Forward-looking statements are not guarantees of future performance. Although we believe that the expectations reflected in our forward-looking statements are reasonable, we do not know whether our expectations will prove correct. All forward-looking statements included in this press release are expressly qualified in their entirety by the foregoing cautionary statements. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of today's date. We do not undertake any obligation to update, amend or clarify these statements or the 'Risk Factors' contained in our most recent reports filed with the SEC, whether as a result of new information, future events or otherwise, except as may be required under the applicable securities laws. View source version on Disclaimer: The above press release comes to you under an arrangement with Business Wire. Business Upturn takes no editorial responsibility for the same.
